MX2022014675A - Sistema, metodo y uso de un determinado medicamento para reducir la replicacion viral en la mucosa de las vias respiratorias. - Google Patents
Sistema, metodo y uso de un determinado medicamento para reducir la replicacion viral en la mucosa de las vias respiratorias.Info
- Publication number
- MX2022014675A MX2022014675A MX2022014675A MX2022014675A MX2022014675A MX 2022014675 A MX2022014675 A MX 2022014675A MX 2022014675 A MX2022014675 A MX 2022014675A MX 2022014675 A MX2022014675 A MX 2022014675A MX 2022014675 A MX2022014675 A MX 2022014675A
- Authority
- MX
- Mexico
- Prior art keywords
- certain
- viral replication
- medication
- mucosae
- certain medication
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 230000029812 viral genome replication Effects 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 230000005540 biological transmission Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Un sistema, un método, un uso, una combinación y unos kits farmacéuticos útiles para la administración de un determinado medicamento para reducir la replicación viral de ciertos virus durante la fase inicial de la transmisión o como profilaxis cuando se detecta o predice un alto riesgo de exposición a un virus, administrando eficazmente una alta concentración local del determinado medicamento al tiempo que se minimiza la exposición sistémica. Específicamente, se refiere a un sistema, un método, un uso, una combinación y kits farmacéuticos de un determinado medicamento nebulizado para reducir la replicación viral. El desarrollo utiliza inhaladores o nebulizadores para administrar al menos un determinado medicamento directamente en las mucosas de las vías respiratorias superiores e inferiores.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063028714P | 2020-05-22 | 2020-05-22 | |
| US202163182125P | 2021-04-30 | 2021-04-30 | |
| PCT/IB2021/054451 WO2021234668A1 (en) | 2020-05-22 | 2021-05-21 | System, method and use of a certain medication for reducing viral replication in the airways mucosae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014675A true MX2022014675A (es) | 2023-02-14 |
Family
ID=78607660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014675A MX2022014675A (es) | 2020-05-22 | 2021-05-21 | Sistema, metodo y uso de un determinado medicamento para reducir la replicacion viral en la mucosa de las vias respiratorias. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210361688A1 (es) |
| EP (1) | EP4153157A4 (es) |
| JP (1) | JP2023526547A (es) |
| KR (1) | KR20230074065A (es) |
| CN (1) | CN116033894A (es) |
| AU (1) | AU2021276693A1 (es) |
| BR (1) | BR112022023746A2 (es) |
| CA (1) | CA3179698A1 (es) |
| IL (1) | IL298410A (es) |
| MX (1) | MX2022014675A (es) |
| UY (1) | UY39226A (es) |
| WO (2) | WO2021234668A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4103218A4 (en) * | 2020-02-10 | 2024-05-01 | Oncoimmune Inc | METHOD OF USING SOLUBLE CD24 TO TREAT SARS-COV-2 INFECTIONS |
| WO2021234668A1 (en) * | 2020-05-22 | 2021-11-25 | Riveros Carlos Alberto | System, method and use of a certain medication for reducing viral replication in the airways mucosae |
| US11857617B2 (en) | 2021-05-10 | 2024-01-02 | Topelia Aust Limited (652 771 670) | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment |
| KR20240035513A (ko) | 2021-07-09 | 2024-03-15 | 알리고스 테라퓨틱스 인코포레이티드 | 항바이러스 화합물 |
| WO2023003003A1 (ja) * | 2021-07-20 | 2023-01-26 | 興和株式会社 | 新規吸入剤 |
| CN114957078A (zh) * | 2022-01-19 | 2022-08-30 | 广州谷森制药有限公司 | 一种氘代医药中间体的制备方法 |
| WO2023192779A2 (en) * | 2022-03-31 | 2023-10-05 | Asavi Llc | Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| US7129042B2 (en) * | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
| EP2215108A4 (en) * | 2007-10-23 | 2012-07-04 | Univ Colorado | COMPETITIVE INHIBITORS OF THE EXPRESSION OF THE CONSTANT CHAIN AND / OR THE ECTOPIC CLIP BINDING |
| WO2010142017A1 (en) * | 2009-06-09 | 2010-12-16 | Defyrus, Inc . | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
| US11491123B2 (en) * | 2016-06-23 | 2022-11-08 | Health Research, Inc. | Pharmaceutical compositions with antiflaviviral activity |
| JP7466907B2 (ja) * | 2017-10-18 | 2024-04-15 | ヴァーシテック・リミテッド | 広域スペクトルの抗ウイルス治療のための組成物及び方法 |
| EP4117657A4 (en) * | 2020-03-13 | 2024-04-24 | Univ Monash | VIRAL INHIBITION |
| WO2021234668A1 (en) * | 2020-05-22 | 2021-11-25 | Riveros Carlos Alberto | System, method and use of a certain medication for reducing viral replication in the airways mucosae |
-
2021
- 2021-05-21 WO PCT/IB2021/054451 patent/WO2021234668A1/en unknown
- 2021-05-21 AU AU2021276693A patent/AU2021276693A1/en active Pending
- 2021-05-21 KR KR1020227045219A patent/KR20230074065A/ko unknown
- 2021-05-21 US US17/327,306 patent/US20210361688A1/en active Pending
- 2021-05-21 JP JP2022571809A patent/JP2023526547A/ja active Pending
- 2021-05-21 IL IL298410A patent/IL298410A/en unknown
- 2021-05-21 CN CN202180037080.6A patent/CN116033894A/zh active Pending
- 2021-05-21 BR BR112022023746A patent/BR112022023746A2/pt not_active Application Discontinuation
- 2021-05-21 CA CA3179698A patent/CA3179698A1/en active Pending
- 2021-05-21 MX MX2022014675A patent/MX2022014675A/es unknown
- 2021-05-21 UY UY0001039226A patent/UY39226A/es unknown
- 2021-05-21 EP EP21809228.6A patent/EP4153157A4/en active Pending
-
2022
- 2022-05-21 WO PCT/IB2022/054767 patent/WO2022243981A1/es active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA3179698A1 (en) | 2021-11-25 |
| EP4153157A4 (en) | 2024-06-05 |
| CN116033894A (zh) | 2023-04-28 |
| UY39226A (es) | 2021-12-31 |
| AU2021276693A1 (en) | 2023-01-05 |
| EP4153157A1 (en) | 2023-03-29 |
| KR20230074065A (ko) | 2023-05-26 |
| US20210361688A1 (en) | 2021-11-25 |
| WO2021234668A1 (en) | 2021-11-25 |
| BR112022023746A2 (pt) | 2023-02-07 |
| IL298410A (en) | 2023-01-01 |
| JP2023526547A (ja) | 2023-06-21 |
| WO2022243981A1 (es) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014675A (es) | Sistema, metodo y uso de un determinado medicamento para reducir la replicacion viral en la mucosa de las vias respiratorias. | |
| Clementi et al. | Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro | |
| Boban | Novel coronavirus disease (COVID‐19) update on epidemiology, pathogenicity, clinical course and treatments | |
| Barton et al. | Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting | |
| Echeverria et al. | Enflurane and halothane in status asthmaticus | |
| PA8744101A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| Klassen | Croup: a current perspective | |
| BR112022014578A2 (pt) | Composição e métodos de profiláticos e terapêuticos de rnai para o tratamento de infecção respiratória aguda grave causada pelo novo coronavírus 2019 (2019-ncov) | |
| Jin et al. | Pulmonary delivery of the Kv1. 3-blocking peptide HsTX1 [R14A] for the treatment of autoimmune diseases | |
| WO2022111497A1 (zh) | 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用 | |
| KR20120098699A (ko) | 인플루엔자 치료용 재조합 사람 ｃｃ10 단백질 | |
| Kuitert et al. | Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| Gatti et al. | Therapeutic strategies for COVID-19 lung disease in children | |
| MohammadSadeghi et al. | Pharmacotherapy for reducing saliva and droplet production in airborne procedures may help to decrease the COVID-19 transmission: A hypothesis | |
| Cardenas et al. | Role of systemic and nasal glucocorticoid treatment in the regulation of the inflammatory response in patients with SARS-Cov-2 infection | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| BR112020013750A8 (pt) | Dispensação intranasal de olanzapina por dispositivo olfativo de precisão | |
| AU2021254262A1 (en) | Methods for treatment of coronavirus infections | |
| Dasenbrook et al. | Anti-inflammatory therapies for cystic fibrosis | |
| US20230330180A1 (en) | Antiviral compositions and methods | |
| Girkin et al. | Upper respiratory tract OC43 infection model for investigating airway immune-modifying therapies | |
| Yatomi et al. | Improvement of Severe COVID‐19 in an Elderly Man by Sequential Use of Antiviral Drugs | |
| Ribas | COVID-19: A therapeutic approach based on pathophysiological staging |